CRINETICS PHARMACEUTICALS IN (CRNX) Stock Earnings & Estimates
USA - NASDAQ:CRNX - US22663K1079 - Common Stock
42.06 USD
-2.28 (-5.14%)
42.26 USD
+0.2 (+0.48%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 4.74M 338.89% | 4.013M -15.34% | 1.039M -74.11% | 5.411M 420.79% | 59.188M 993.85% | 185.44M 213.31% | 506.88M 173.34% | 1.117B 120.37% | 1.94B 73.68% | 3.073B 58.40% | 4.487B 46.01% | |
| EBITDA YoY % growth | -166.9M -56.30% | -221.51M -32.72% | -336.069M -51.72% | -476.007M -41.64% | -500.398M -5.12% | -376.343M 24.79% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -167.88M -55.88% | -222.608M -32.60% | -338.854M -52.22% | -510.205M -50.57% | -544.332M -6.69% | -400.021M 26.51% | -193.318M 51.67% | 287.39M 248.66% | 963.63M 235.30% | 1.845B 91.46% | 2.976B 61.30% | |
| Operating Margin | -3,541.77% | -5,547.17% | -32,613.47% | -9,429.03% | -919.67% | -215.71% | -38.14% | 25.73% | 49.67% | 60.04% | 66.32% | |
| EPS YoY % growth | -3.14 -12.14% | -3.70 -17.83% | -3.71 -0.27% | -4.92 -32.75% | -5.15 -4.49% | -3.92 23.86% | -1.55 60.36% | 2.66 271.59% | 8.43 216.43% | 14.45 71.33% | 22.43 55.28% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.28 -33.40% | -1.31 -49.03% | -1.37 -31.47% | -1.38 -11.83% | -1.39 -8.51% | -1.39 -5.62% |
| Revenue Q2Q % growth | 390.507K | 3.471M | 6.716M 1,760.39% | 9.345M 806.40% | 12.071M 2,991.11% | 16.002M 361.02% |
| EBITDA Q2Q % growth | -111.403M -29.84% | -116M -26.14% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -129.569M -47.58% | -134.515M -41.98% | -140.111M -25.77% | -138.584M -7.34% | -144.354M -11.41% | -146.543M -8.94% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -1.23 -30.85% | -1.12 | -0.11 | -9.79% |
| Q1 2025 Q2Q % growth | -1.04 -11.83% | -0.96 | -0.08 | -8.34% |
| Q4 2024 Q2Q % growth | -0.88 2.22% | -0.91 | 0.03 | 2.94% |
| Q3 2024 Q2Q % growth | -0.96 4.95% | -0.93 | -0.03 | -3.35% |
| Q2 2024 Q2Q % growth | -0.94 | -0.88 | -0.06 | -7.29% |
| Q1 2024 Q2Q % growth | -0.93 -9.41% | -0.83 | -0.10 | -12.64% |
| Q4 2023 Q2Q % growth | -0.90 -7.14% | -0.88 | -0.02 | -2.31% |
| Q3 2023 Q2Q % growth | -1.01 -29.49% | -0.88 | -0.13 | -15.29% |
| Q2 2023 Q2Q % growth | -0.94 -16.05% | -0.87 | -0.07 | -7.46% |
| Q1 2023 Q2Q % growth | -0.85 -19.72% | -0.83 | -0.02 | -2.64% |
| Q4 2022 Q2Q % growth | -0.84 -23.53% | -0.84 | 0.00 | -0.23% |
| Q3 2022 Q2Q % growth | -0.78 -6.85% | -0.85 | 0.07 | 8.05% |
| Q2 2022 Q2Q % growth | -0.81 -15.71% | -0.69 | -0.12 | -17.94% |
| Q1 2022 Q2Q % growth | -0.71 -2.90% | -0.59 | -0.12 | -20.01% |
| Q4 2021 Q2Q % growth | -0.68 -3.03% | -0.64 | -0.04 | -6.67% |
| Q3 2021 Q2Q % growth | -0.73 -30.36% | -0.73 | 0.00 | 0.04% |
| Q2 2021 Q2Q % growth | -0.70 -32.08% | -0.62 | -0.08 | -12.50% |
| Q1 2021 Q2Q % growth | -0.69 2.82% | -0.67 | -0.02 | -2.50% |
| Q4 2020 Q2Q % growth | -0.66 -10.00% | -0.59 | -0.07 | -11.95% |
| Q3 2020 Q2Q % growth | -0.56 6.67% | -0.54 | -0.02 | -4.38% |
| Q2 2020 Q2Q % growth | -0.53 -3.92% | -0.58 | 0.05 | 8.20% |
| Q1 2020 Q2Q % growth | -0.71 -91.89% | -0.64 | -0.07 | -10.49% |
| Q4 2019 Q2Q % growth | -0.60 | -0.69 | 0.09 | 13.07% |
| Q3 2019 Q2Q % growth | -0.60 | -0.58 | -0.02 | -3.56% |
| Q2 2019 Q2Q % growth | -0.51 | -0.47 | -0.04 | -9.65% |
| Q1 2019 Q2Q % growth | -0.37 | -0.42 | 0.05 | 11.53% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 1.031M 158.40% | 131.753K | 899.247K | 682.52% |
| Q1 2025 Q2Q % growth | 361K -43.59% | 92.728K | 268.272K | 289.31% |
| Q4 2024 Q2Q % growth | 738.113K | -738.113K | -100.00% | |
| Q3 2024 Q2Q % growth | -100.00% | 244.8K | -244.8K | -100.00% |
| Q2 2024 Q2Q % growth | 399K -59.62% | 520.2K | -121.2K | -23.30% |
| Q1 2024 Q2Q % growth | 640K -76.11% | 260.671K | 379.329K | 145.52% |
| Q4 2023 Q2Q % growth | -100.00% | 265.2K | -265.2K | -100.00% |
| Q3 2023 Q2Q % growth | 346K -24.78% | 125.97K | 220.03K | 174.67% |
| Q2 2023 Q2Q % growth | 988K 124.55% | 574.433K | 413.567K | 72.00% |
| Q1 2023 Q2Q % growth | 2.679M -14.41% | 351.023K | 2.328M | 663.20% |
| Q4 2022 Q2Q % growth | 710K -34.26% | 255K | 455K | 178.43% |
| Q3 2022 Q2Q % growth | 460K | 170.003K | 289.997K | 170.58% |
| Q2 2022 Q2Q % growth | 440K | 612K | -172K | -28.10% |
| Q1 2022 Q2Q % growth | 3.13M | 5.304M | -2.174M | -40.99% |
| Q1 2021 Q2Q % growth | -100.00% | % | ||
| Q4 2020 Q2Q % growth | -100.00% | % | ||
| Q3 2020 Q2Q % growth | -100.00% | % | ||
| Q1 2020 Q2Q % growth | 70K -81.08% | 70K | % | |
| Q4 2019 Q2Q % growth | 320K | 110.497K | 209.503K | 189.60% |
| Q3 2019 Q2Q % growth | 510K | 153K | 357K | 233.33% |
| Q2 2019 Q2Q % growth | 153K | -153K | -100.00% | |
| Q1 2019 Q2Q % growth | 370K | 132.6K | 237.4K | 179.03% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -1.34% | -7% | -1.59% | -7.51% |
| Revenue | -39.92% | -9.92% | -8.57% | 3.74% |